NIOX Group (LON:NIOX) Stock Falls 4.3% – What’s Next?

NIOX Group Plc (LON:NIOX)’s share price traded down 4.3% on Wednesday. The stock traded as low as GBX 66 and last traded at GBX 66. 447,932 shares were traded during mid-day trading, a decline of 42% from the average session volume of 769,979 shares. The stock had previously closed at GBX 69.

NIOX Group Stock Up 1.5%

The firm has a 50-day moving average of GBX 67.29 and a two-hundred day moving average of GBX 62.72. The company has a quick ratio of 1.94, a current ratio of 4.60 and a debt-to-equity ratio of 1.06. The company has a market capitalization of £289.56 million, a PE ratio of 42.21 and a beta of 0.92.

NIOX Group (LON:NIOX) last posted its earnings results on Wednesday, September 30th. The company reported GBX 1.41 EPS for the quarter. NIOX Group had a return on equity of 10.01% and a net margin of 14.74%. Equities research analysts predict that NIOX Group Plc will post 1.17 earnings per share for the current fiscal year.

About NIOX Group

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.